文献速递流行病学与生物统计临床试验与 GCP

住院急性病患者血栓预防的抗凝药物:系统评价与网状Meta分析

Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis.
PubMed 文献 · BMJ · 2022-07-04

该系统评价与网状Meta分析纳入44项随机对照试验共90095例急性入院成人患者,评估不同种类和剂量抗凝药物预防静脉血栓栓塞的获益与危害。低至中等质量证据显示,中等剂量低分子肝素在获益与危害间平衡最佳,普通肝素(尤其中等剂量)和直接口服抗凝药表现最差。作者指出证据质量普遍低至中等,且存在统计不一致性。

要点

  • 中等剂量低分子肝素在预防静脉血栓栓塞方面似乎获益与危害平衡最佳。
  • 普通肝素(尤其中等剂量)和直接口服抗凝药的安全性特征最不理想。
  • 与安慰剂相比,无干预作为参照时各干预效应出现系统性差异。

核心结论

  • 中等剂量低分子肝素似乎为预防静脉血栓栓塞提供最佳的获益与危害平衡。
  • 普通肝素尤其是中等剂量以及直接口服抗凝药的安全性特征最不理想。
  • 干预效应取决于以安慰剂还是无干预为参照治疗,存在系统性差异。

研究设计与样本

  • 系统评价与网状Meta分析,检索Cochrane CENTRAL、PubMed/Medline、Embase、Web of Science、临床试验注册库及国家卫生主管部门数据库,最后更新至2021年11月16日。
  • 纳入已发表和未发表的随机对照试验,评估低或中等剂量低分子肝素、低或中等剂量普通肝素、直接口服抗凝药、戊多糖、安慰剂或无干预用于住院急性病成人患者静脉血栓栓塞预防。
  • 共纳入44项随机对照试验,随机分配90095例参与者进入主要分析。
  • 采用随机效应贝叶斯网状Meta分析,四个共同主要结局为全因死亡、症状性静脉血栓栓塞、大出血和严重不良事件(取最接近90天的时间点)。
  • 使用Cochrane偏倚风险2.0工具评估偏倚风险,采用CINeMA框架对证据质量进行分级。

主要发现

  • 低至中等质量证据提示,与安慰剂相比,没有任何干预降低全因死亡。
  • 戊多糖(比值比0.32,95%可信区间0.08至1.07)、中等剂量低分子肝素(0.66,0.46至0.93)、直接口服抗凝药(0.68,0.33至1.34)和中等剂量普通肝素(0.71,0.43至1.19)最有可能降低症状性静脉血栓栓塞(极低至低质量证据)。
  • 中等剂量普通肝素(2.63,1.00至6.21)和直接口服抗凝药(2.31,0.82至6.47)最有可能增加大出血(低至中等质量证据)。
  • 各干预之间在严重不良事件方面未观察到确切差异(极低至低质量证据)。
  • 与无干预而非安慰剂比较时,所有活性干预在静脉血栓栓塞和死亡风险方面表现更有利,在大出血风险方面表现更不利。

关键数值与推荐

  • 戊多糖降低症状性静脉血栓栓塞的比值比0.32(95%可信区间0.08至1.07),极低至低质量证据。
  • 中等剂量低分子肝素降低症状性静脉血栓栓塞的比值比0.66(95%可信区间0.46至0.93),极低至低质量证据。
  • 直接口服抗凝药降低症状性静脉血栓栓塞的比值比0.68(95%可信区间0.33至1.34),极低至低质量证据。
  • 中等剂量普通肝素降低症状性静脉血栓栓塞的比值比0.71(95%可信区间0.43至1.19),极低至低质量证据。
  • 中等剂量普通肝素增加大出血的比值比2.63(95%可信区间1.00至6.21),低至中等质量证据;直接口服抗凝药增加大出血的比值比2.31(95%可信区间0.82至6.47),低至中等质量证据。

临床怎么用

  • 原文未据此给出推荐。
  • 作者结论认为中等剂量低分子肝素似乎提供最佳的获益与危害平衡。
  • 作者结论认为普通肝素尤其是中等剂量以及直接口服抗凝药的安全性特征最不理想。

局限性

  • 主要局限性包括证据质量普遍低至中等,原因在于不精确性和研究内偏倚。
  • 存在统计不一致性,该问题在事后进行处理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the benefits and harms of different types and doses of anticoagulant drugs for the prevention of venous thromboembolism in patients who are acutely ill and admitted to hospital. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Cochrane CENTRAL, PubMed/Medline, Embase, Web of Science, clinical trial registries, and national health authority databases. The search was last updated on 16 November 2021. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Published and unpublished randomised controlled trials that evaluated low or intermediate dose low-molecular-weight heparin, low or intermediate dose unfractionated heparin, direct oral anticoagulants, pentasaccharides, placebo, or no intervention for the prevention of venous thromboembolism in acutely ill adult patients in hospital. MAIN OUTCOME MEASURES: Random effects, bayesian network meta-analyses used four co-primary outcomes: all cause mortality, symptomatic venous thromboembolism, major bleeding, and serious adverse events at or closest timing to 90 days. Risk of bias was also assessed using the Cochrane risk-of-bias 2.0 tool. The quality of evidence was graded using the Confidence in Network Meta-Analysis framework. RESULTS: 44 randomised controlled trials that randomly assigned 90 095 participants were included in the main analysis. Evidence of low to moderate quality suggested none of the interventions reduced all cause mortality compared with placebo. Pentasaccharides (odds ratio 0.32, 95% credible interval 0.08 to 1.07), intermediate dose low-molecular-weight heparin (0.66, 0.46 to 0.93), direct oral anticoagulants (0.68, 0.33 to 1.34), and intermediate dose unfractionated heparin (0.71, 0.43 to 1.19) were most likely to reduce symptomatic venous thromboembolism (very low to low quality evidence). Intermediate dose unfractionated heparin (2.63, 1.00 to 6.21) and direct oral anticoagulants (2.31, 0.82 to 6.47) were most likely to increase major bleeding (low to moderate quality evidence). No conclusive differences were noted between interventions regarding serious adverse events (very low to low quality evidence). When compared with no intervention instead of placebo, all active interventions did more favourably with regard to risk of venous thromboembolism and mortality, and less favourably with regard to risk of major bleeding. The results were robust in prespecified sensitivity and subgroup analyses. CONCLUSIONS: Low-molecular-weight heparin in an intermediate dose appears to confer the best balance of benefits and harms for prevention of venous thromboembolism. Unfractionated heparin, in particular the intermediate dose, and direct oral anticoagulants had the least favourable profile. A systematic discrepancy was noted in intervention effects that depended on whether placebo or no intervention was the reference treatment. Main limitations of this study include the quality of the evidence, which was generally low to moderate due to imprecision and within-study bias, and statistical inconsistency, which was addressed post hoc. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020173088.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Eck RJ, Elling T, Sutton AJ, et al. Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis. BMJ. 2022. PMID: 35788047. doi:10.1136/bmj-2022-070022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。